Seamus Fernandez
Stock Analyst at Guggenheim
(4.92)
# 38
Out of 5,090 analysts
113
Total ratings
68.75%
Success rate
70.57%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IVA Inventiva | Maintains: Buy | $13 → $11 | $4.15 | +165.06% | 1 | Nov 18, 2025 | |
| CDTX Cidara Therapeutics | Downgrades: Neutral | n/a | $220.60 | - | 6 | Nov 18, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $84 → $77 | $30.41 | +153.21% | 4 | Nov 10, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Neutral | n/a | $6.89 | - | 4 | Oct 23, 2025 | |
| LLY Eli Lilly and Company | Reiterates: Buy | $948 | $1,020.28 | -7.08% | 20 | Oct 16, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $17 → $25 | $14.86 | +68.24% | 2 | Sep 15, 2025 | |
| TENX Tenax Therapeutics | Maintains: Buy | $15 → $14 | $9.34 | +49.89% | 2 | Aug 14, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $92 → $90 | $32.60 | +176.12% | 2 | Aug 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $119 → $120 | $105.27 | +13.99% | 2 | Aug 6, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $116 | $75.44 | +53.77% | 8 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $30.82 | - | 3 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $45.97 | +248.09% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $39.42 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $101.43 | +20.28% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.41 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.30 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $51.78 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $48.69 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $133.98 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.10 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $2.95 | +1,730.51% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $29.43 | +52.91% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $90.98 | -58.23% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $25.72 | +47.77% | 3 | Jan 31, 2018 |
Inventiva
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $4.15
Upside: +165.06%
Cidara Therapeutics
Nov 18, 2025
Downgrades: Neutral
Price Target: n/a
Current: $220.60
Upside: -
MBX Biosciences
Nov 10, 2025
Maintains: Buy
Price Target: $84 → $77
Current: $30.41
Upside: +153.21%
Arcturus Therapeutics Holdings
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $6.89
Upside: -
Eli Lilly and Company
Oct 16, 2025
Reiterates: Buy
Price Target: $948
Current: $1,020.28
Upside: -7.08%
Amylyx Pharmaceuticals
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $14.86
Upside: +68.24%
Tenax Therapeutics
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $9.34
Upside: +49.89%
Structure Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $92 → $90
Current: $32.60
Upside: +176.12%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $119 → $120
Current: $105.27
Upside: +13.99%
Apogee Therapeutics
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $75.44
Upside: +53.77%
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $30.82
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $45.97
Upside: +248.09%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $39.42
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $101.43
Upside: +20.28%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $48.41
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.30
Upside: -
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $51.78
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $48.69
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $133.98
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.10
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $2.95
Upside: +1,730.51%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $29.43
Upside: +52.91%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $90.98
Upside: -58.23%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $25.72
Upside: +47.77%